newsfilter
← Earnings
Earnings Releases·

Alamar Biosciences — Third Quarter 2026 Earnings Summary

Alamar Biosciences reported third-quarter 2026 total revenue of $33.5 million, representing a 68% increase from the same period in 2025. The company raised its full-year 2026 revenue guidance to a range of $121 million to $123 million, reflecting strong demand for its consumables and services. Key operational milestones included a strategic collaboration with GSK for a 60,000-sample study and selection by the UK Biobank to profile 80,000 samples for neurodegenerative disease research. Additionally, the company announced the retirement of President Tod White at the end of 2026, who will transition to an advisory role through June 2027.

Company
ALAMAR BIOSCIENCES INC
Sector
Healthcare
Industry
Medical Devices